EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis

Aracely Acevedo, Anthony E Jones, Bezawit T Danna, Rory Turner, Katrina P Montales, Cristiane Benincá, Karen Reue, Orian S Shirihai, Linsey Stiles, Martina Wallace, Yibin Wang, Ambre M Bertholet und 1 weitere

Journal of Biological Chemistry · 2024-03 · 300 (3) · 105702

DOI: 10.1016/j.jbc.2024.105702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-03. Verfasst von Aracely Acevedo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Lipogenesis, Metabolic Diseases, Mitochondrial Membranes, Protein Kinase Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elevated levels of branched chain amino acids (BCAAs) and branched-chain α-ketoacids are associated with cardiovascular and metabolic disease, but the molecular mechanisms underlying a putative causal relationship remain unclear. The branched-chain ketoacid dehydrogenase kinase (BCKDK) inhibitor BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) is often used in preclinical models to increase BCAA oxidation and restore steady-state BCAA and branched-chain α-ketoacid levels. BT2 administration is protective in various rodent models of heart failure and metabolic disease, but confoundingly, targeted ablation of Bckdk in specific tissues does not reproduce the beneficial effects conferred by pharmacologic inhibition. Here, we demonstrate that BT2, a lipophilic weak acid, can act as a mitochondrial uncoupler. Measurements of oxygen consumption, mitochondrial membrane potential, and patch-clamp electrophysiology show that BT2 increases proton conductance across the mitochondrial inner membrane independently of its inhibitory effect on BCKDK. BT2 is roughly sixfold less potent than the prototypical uncoupler 2,4-dinitrophenol and phenocopies 2,4-dinitrophenol in lowering de novo lipogenesis and mitochondrial superoxide production. The data suggest that the therapeutic efficacy of BT2 may be attributable to the well-documented effects of mitochondrial uncoupling in alleviating cardiovascular and metabolic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipogenesisMetabolic DiseasesMitochondrial MembranesProtein Kinase InhibitorsReactive Oxygen SpeciesAnimalsHumansMiceRats2,4-Dinitrophenol3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)Amino Acids, Branched-ChainCell LineCells, CulturedProtein Kinases

Stichwörter der Autor:innen

BT2ROS productionbranched-chain amino acidscardiometabolic diseasechemical uncouplingmitochondria

Substanzen

2,4-Dinitrophenol3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)Amino Acids, Branched-ChainProtein Kinase InhibitorsReactive Oxygen SpeciesBCKDK protein, humanProtein Kinases

Autor:innen und Institutionen

  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
  • School of Agriculture and Food Science, University College Dublin, Dublin, Ireland.
  • Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Human Genetics, University of California, Los Angeles, Los Angeles, California, USA.
  • DukeNUS School of Medicine, Signature Research Program in Cardiovascular and Metabolic Diseases, Singapore, Singapore.
  • Department of Physiology, University of California, Los Angeles, Los Angeles, California, USA.

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • PEW Charitable Trusts
  • US Department of Defense
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • University of California, Los Angeles

Zitieren

APA

Acevedo, A., Jones, A. E., Danna, B. T., Turner, R., Montales, K. P., Benincá, C., Reue, K., Shirihai, O. S., Stiles, L., Wallace, M., Wang, Y., Bertholet, A. M., & Divakaruni, A. S. (2024). The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis. Journal of Biological Chemistry, 300(3), 105702. https://doi.org/10.1016/j.jbc.2024.105702

Vancouver

Acevedo A, Jones AE, Danna BT, Turner R, Montales KP, Benincá C, et al. The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis. Journal of Biological Chemistry. 2024;300(3):105702. doi:10.1016/j.jbc.2024.105702

BibTeX
@article{Acevedo2024,
  author = {Acevedo, Aracely and Jones, Anthony E and Danna, Bezawit T and Turner, Rory and Montales, Katrina P and Benincá, Cristiane and Reue, Karen and Shirihai, Orian S and Stiles, Linsey and Wallace, Martina and Wang, Yibin and Bertholet, Ambre M and Divakaruni, Ajit S},
  title = {The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  volume = {300},
  number = {3},
  pages = {105702},
  doi = {10.1016/j.jbc.2024.105702}
}
Kostenlos starten →